CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Which has lower capital gains taxes between ETF and mutual funds in retirement contexts? A concise comparison of tax profiles and practical tips.
28,445 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Nebius stock's massive upside sits at the intersection of rising AI demand and heavy capital needs. This article brea...
Rackspace Technology posts a tighter loss and higher 2026 profit outlook after a solid Q4, even as shares slip follow...
Runlayer closed a $30 million Series A led by FELICIS with Khosla Ventures joining, bringing total funding to $42 mil...
Nike faces a pivotal earnings moment as June 30 approaches. This guide breaks down whether you should nike stock befo...
As AI workloads surge, investors wonder if Applied Digital could be an undervalued play. This guide breaks down how t...
EchoStar joined the S&P 500 on March 23, 2026, carrying unusually high short interest. This article examines the setu...
Strategy MSTR short interest is rising as bearish bets mount, challenging the narrative around the companys Bitcoin s...
June 11 brought a surprising twist: Coupang’s privacy fine landed below feared levels, sending the stock higher and l...
Narrowing the lens on rare earths reveals how policy shifts, EV demand, and new mines could shape USA Rare Earth's st...
Sidus Space (SIDU) 2025 presents a micro-cap story in the space economy. This article breaks down the business, what ...
Vietnam and the Philippines have been upgraded to upper-middle-income status, signaling a new growth phase and bringi...